Melody Cobleigh to Trastuzumab
This is a "connection" page, showing publications Melody Cobleigh has written about Trastuzumab.
Connection Strength
2.218
-
Comparison of Radiation With or Without Concurrent Trastuzumab for HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy: A Phase III Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2367-2374.
Score: 0.742
-
Loss of STAT6 leads to anchorage-independent growth and trastuzumab resistance in HER2+ breast cancer cells. PLoS One. 2020; 15(6):e0234146.
Score: 0.703
-
Trastuzumab-induced cardiac toxicity: Is serial assessment of left ventricular ejection fraction during treatment necessary? Breast J. 2020 05; 26(5):1085-1086.
Score: 0.169
-
Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent? JAMA Oncol. 2016 Sep 01; 2(9):1123-4.
Score: 0.135
-
Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. Ann Oncol. 2016 06; 27(6):1029-1034.
Score: 0.131
-
A case of herceptin cardiotoxicity. Am J Ther. 2004 Jan-Feb; 11(1):74-6.
Score: 0.056
-
Is trastuzumab every three weeks ready for prime time? J Clin Oncol. 2003 Nov 01; 21(21):3900-1.
Score: 0.055
-
Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Res Treat. 2021 Jul; 188(1):179-190.
Score: 0.046
-
De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist. 2020 02; 25(2):e214-e222.
Score: 0.042
-
Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates. Cancer Chemother Pharmacol. 2014 Aug; 74(2):399-410.
Score: 0.029
-
Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. Breast Cancer Res Treat. 2013 Nov; 142(2):415-21.
Score: 0.028
-
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18):2786-92.
Score: 0.017
-
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005 Aug; 6(3):240-6.
Score: 0.016
-
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004 Mar 15; 22(6):1063-70.
Score: 0.014
-
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002 Feb 01; 20(3):719-26.
Score: 0.012
-
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report. Eur J Cancer. 2001 Jan; 37 Suppl 1:S25-9.
Score: 0.011
-
First-line Herceptin monotherapy in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:37-42.
Score: 0.011